Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGASUS: Degarelix vs GnRH Agonist + RT in High-Risk Prostate Cancer
NCT02799706Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2017
- Primary completion
- Aug 2023
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of degarelix in prostate cancer (PCa), sponsored by European Organisation for Research and Treatment of Cancer. Started Sep 2017; status: active, not recruiting.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02799706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799706.